The time for a Sarepta Therapeutics takeover is ‘ripe’ state analysts
The time for a Sarepta Therapeutics (SRPT) takeover is ‘ripe’ states analyst
SRPT
-0.15%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
By Sam Boughedda
Oppenheimer analysts said in a note Friday that Sarepta Therapeutics Sarepta Therapeutics Inc (NASDAQ:SRPT) is «ripe» for a takeover.
The analysts, who have an Outperform rating and a $150 price target on the stock, explained that while the M&A Buy thesis for Sarepta has been explained well, they believe the timing might be «more ripe currently.»
Sarepta Therapeutics shares are down 0.4% at the time of writing. However, they have climbed 27% so far in 2022.
Oppenheimer upgraded Sarepta in December last year, stating it had a «best-in-class rh74 AAV capsid.»
In today’s note, the analysts wrote: «The best-in-class safety profile for SRPT’s rh74 AAV vector is bolstered by the company’s leading manufacturing expertise in this area; possibly creating a significant moat around the muscular dystrophy programs. The LGMD programs and the RNA-based PPMO programs are underappreciated. We stay bullish.»
«The optics for a SRPT takeout are easy, in our view: (1) a leader in gene therapy, (2) a leader in muscular dystrophies (DMD, LGMDs), (3) a fairly diverse pipeline with RNA-targeted therapies and gene editing approaches also, and (4) a strong financial backdrop to achieve its objective to be a leader in genetic medicines in rare diseases. We add some nuance to these views,» they added.